RxDoctor Payments Data

Meredith Rivenbark, PA

Physician Assistant · Greenville, SCNPI 1679190284

Payments from drug & device makers

$4,407in general payments, 2019–2025

Across 179 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$624
  • Johnson & Johnson$425
  • Takeda Pharmaceuticals U.S.A., Inc.$314
  • Regeneron Healthcare Solutions, Inc.$270
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$215
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,33298%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,407 in reported general payments places this provider in the 85th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$15,027
Medicare patients
154
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid25$230,885
ZenpepLipase/Protease/Amylase24$86,473
XifaxanRifaximin15$51,446
LinzessLinaclotide31$36,719
Mesalamine21$8,232
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates104$7,194
Sucralfate14$5,656
CholestyramineCholestyramine (With Sugar)14$1,703
Omeprazole87$1,316
Pantoprazole Sodium53$1,170
Ondansetron OdtOndansetron38$617
Dicyclomine Hcl29$442
Lactulose16$294
Spironolactone11$271
Famotidine29$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$13$230,88525 claims
Aimmune Therapeutics, Inc.Zenpep$103$86,47324 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$215$51,44615 claims
AbbVieLinzess$1,370$36,71931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →